Printer Friendly

Acura Pharmaceuticals announces IND for benzodiazepine product candidate.

M2 EUROPHARMA-(C)1999-2010 M2 COMMUNICATIONS

16 March 2010 - US-based specialty pharmaceutical company Acura Pharmaceuticals Inc (NASDAQ: ACUR) announced yesterday clinical evaluation is now allowed under an Investigational New Drug application (IND) filed with the US Food and Drug Administration (FDA) for a benzodiazepine product candidate utilising the company's Aversion Technology.

The primary active ingredient in this product candidate is intended for the treatment of anxiety disorders. Aversion Technology is a unique mixture of active and functional inactive ingredients, intended to minimise abuse liability potential of the primary active ingredient. Benzodiazepine products are classified as Schedule IV for potential abuse by the US Drug Enforcement Administration (DEA). Acura has now opened three INDs for Aversion Technology product candidates.

The 2008 National Survey on Drug Use and Health estimates that 21.5 million people have abused prescription tranquilisers at some point in their lifetime and 5.1 million have abused tranquilisers in the past year.

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 16, 2010
Words:154
Previous Article:Watson Pharmaceuticals gets FDA approval for generic equivalent to Cardizem LA.
Next Article:FDA panel recommends approval of Medtronic DBS Therapy for epilepsy.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters